Patrick Chames

Summary

Country: France

Publications

  1. ncbi Therapeutic antibodies for the treatment of pancreatic cancer
    Patrick Chames
    INSERM U624, GDR2352, Marseille Cedex, France
    ScientificWorldJournal 10:1107-20. 2010
  2. ncbi [The future of antibody fragments, made of a single immunoglobulin domain]
    Patrick Chames
    Anticorps thérapeutiques et immunociblage, INSERM U624, GDR 3260, 163, Avenue de Luminy, 13288 Marseille Cedex 09, France
    Med Sci (Paris) 25:1159-62. 2009
  3. ncbi Bispecific antibodies for cancer therapy: the light at the end of the tunnel?
    Patrick Chames
    INSERM U624 GDR 3260 Marseille, France
    MAbs 1:539-47. 2009
  4. ncbi Phage display and selections on cells
    Klervi Even-Desrumeaux
    INSERM U624, Marseille, France
    Methods Mol Biol 907:225-35. 2012
  5. ncbi Affinity determination of biotinylated antibodies by flow cytometry
    Klervi Even-Desrumeaux
    INSERM U624, Marseille, France
    Methods Mol Biol 907:443-9. 2012
  6. ncbi Phage display and selections on purified antigens
    Julie Matz
    INSERM U624, Marseille, France
    Methods Mol Biol 907:213-24. 2012
  7. ncbi Therapeutic antibodies: successes, limitations and hopes for the future
    Patrick Chames
    Laboratoire d Ingenierie des Systemes Macromoleculaires, CNRS, UPR9027, GDR2352, 31 Chemin Joseph Aiguier, F 13402 Marseille Cedex 20, France
    Br J Pharmacol 157:220-33. 2009
  8. ncbi Strong and oriented immobilization of single domain antibodies from crude bacterial lysates for high-throughput compatible cost-effective antibody array generation
    Klervi Even-Desrumeaux
    INSERM U624, 163 avenue de Luminy case 915, 13288 Marseille Cedex 09, France
    Mol Biosyst 6:2241-8. 2010

Collaborators

  • Klervi Even-Desrumeaux
  • Julie Matz
  • Daniel Baty

Detail Information

Publications8

  1. ncbi Therapeutic antibodies for the treatment of pancreatic cancer
    Patrick Chames
    INSERM U624, GDR2352, Marseille Cedex, France
    ScientificWorldJournal 10:1107-20. 2010
    ....
  2. ncbi [The future of antibody fragments, made of a single immunoglobulin domain]
    Patrick Chames
    Anticorps thérapeutiques et immunociblage, INSERM U624, GDR 3260, 163, Avenue de Luminy, 13288 Marseille Cedex 09, France
    Med Sci (Paris) 25:1159-62. 2009
    ..A new class of antibody fragments, made of a single immunoglobulin domain, is emerging as an exciting alternative. This review describes the outstanding properties and the first achievements of these domain antibodies...
  3. ncbi Bispecific antibodies for cancer therapy: the light at the end of the tunnel?
    Patrick Chames
    INSERM U624 GDR 3260 Marseille, France
    MAbs 1:539-47. 2009
    ..This review describes the most recent advances and clinical study results in the field of bispecific antibodies, a new class of molecules that might outshine conventional mAbs as cancer immunotherapeutics in a near future...
  4. ncbi Phage display and selections on cells
    Klervi Even-Desrumeaux
    INSERM U624, Marseille, France
    Methods Mol Biol 907:225-35. 2012
    ..Finally, several possible variants of the protocol are explained in Subheading 4...
  5. ncbi Affinity determination of biotinylated antibodies by flow cytometry
    Klervi Even-Desrumeaux
    INSERM U624, Marseille, France
    Methods Mol Biol 907:443-9. 2012
    ..Finally, a procedure for K (D) determination by flow cytometry is precisely described...
  6. ncbi Phage display and selections on purified antigens
    Julie Matz
    INSERM U624, Marseille, France
    Methods Mol Biol 907:213-24. 2012
    ..e. panning, or a selection in solution, using a biotinylated antigen as well as the corresponding screening produces, and gives hints on the advantage and drawbacks of each approach...
  7. ncbi Therapeutic antibodies: successes, limitations and hopes for the future
    Patrick Chames
    Laboratoire d Ingenierie des Systemes Macromoleculaires, CNRS, UPR9027, GDR2352, 31 Chemin Joseph Aiguier, F 13402 Marseille Cedex 20, France
    Br J Pharmacol 157:220-33. 2009
    ..This review aims at giving an overview of the current state of the art and describes the most promising avenues that are being followed to create the next generation of antibody-based therapeutic agents...
  8. ncbi Strong and oriented immobilization of single domain antibodies from crude bacterial lysates for high-throughput compatible cost-effective antibody array generation
    Klervi Even-Desrumeaux
    INSERM U624, 163 avenue de Luminy case 915, 13288 Marseille Cedex 09, France
    Mol Biosyst 6:2241-8. 2010
    ....